Treatment with infliximab therapy in psoriasis patients is associated with an increased risk of serious infections compared to those treated with non-biologic disease-modifying antirheumatic drugs (DMARDs) or methotrexate, reveals a prospective study published in the journal British Journal of Dermatology.
Zenas Yiu, The University of Manchester, Manchester, UK, and colleagues conducted the study to compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on non‐biologic systemic therapies.
The investigators grouped several non-biologic systemic therapies, including methotrexate, cyclosporin, acitretin, fumaric acid esters, psoralen-ultraviolet A, or hydroxycarbamide and analyzed rates of serious infections associated with death, hospitalization, or the need for intravenous antimicrobial therapy. Propensity‐score inverse probability treatment weights were used to adjust for potential confounding from a priori identified covariates. Cox proportional hazards models were calculated to obtain hazard ratios.
- Among 3,843 psoriasis patients accrued in the study up to October 2016, the serious infection rates were significantly higher in the infliximab cohort (47.8 per 1,000 person-years) compared with the non-biologic systemic cohort (14.2 per 1,000 person-years).
- the adjusted hazard ratio was 1.95 (95% CI 1.01-3.75 versus DMARDs) and was also higher when compared with methotrexate only (adjusted HR 2.96, 95% CI 1.58-5.57).
- the risk of serious infection was highest in the first 6 months of therapy (adjusted HR 3.49, 95% CI 1.14-10.70).
“Infliximab is associated with an increased risk of serious infections compared with non‐biologic systemic therapies in patients with psoriasis,” concluded the authors.
For more information log on to https://doi.org/10.1111/bjd.17036